Fabry disease

Researchers at The Royal Melbourne Hospital are investigating several new treatments to specifically treat Fabry disease, as well as additional studies to document and monitor the manifestations of disease beyond basic medical care.

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Colitis and Crohn's Disease

The purpose of this study is to determine whether etrolizumab is a safe and effective treatment in patients with moderate to severe active ulcerative colitis that have previously had an unsuccessful response to treatment with immunosuppressants (aka TNF inhibitors - medications that reduces the activation or efficacy of the immune system) such as azathioprine, 6-mercaptopurine, or methotrexate and/or corticosteroids and to see whether etrolizumab is more effective than adalimumab in treating ulcerative colitis.

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Dementia

The main purpose of this study is to track the cognitive, lifestyle and psychological markers of a large group of community-based middle-aged adults (40-65 years inclusive) over five years online, in relation to genetic risk factors that are shown to increase risk of Alzheimer’s disease dementia in older adults.

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Diabetes (Type 1)

We are asking women who are pregnant and have Type 1 Diabetes themselves or have a family member with Type 1 Diabetes who would be a first-degree relative of the baby, i.e. the baby’s father or the baby’s older sibling, to consider participating.

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Colitis and Crohn's Disease

Crohn’s disease is an inflammatory disease of the gastrointestinal tract (digestive tract). The purpose of this study is to see if filgotinib, an experimental drug, is effective and safe in treating people with moderate to severe Crohn’s disease.

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Cancer - Brain

A new anti-epileptic-drug, called perampanel shows promise for being able to control and prevent seizures in patients with brain tumours. There are two separate studies in this project for patients with gliomas, a type of brain tumour.

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Cancer - Breast

Denosumab is approved for use in osteoporosis. Laboratory research has identified other potential effects, including possibly slowing or stopping breast cell growth. The BRCA-D trial aims to investigate the effects of denosumab on normal breast tissue in patients with BRCA 1 or 2 mutations and to determine if the drug has potential to prevent breast cancer. Breast tissue will be obtained and evaluated before and after the denosumab injections.

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Mental Health - Psychosis

The REDUCE study is testing whether or not reducing the dosage of antipsychotic medication of people recovering from their first episode of psychosis can lead to them having better recovery outcomes.

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4